As per the recent CAH Best Practice Guidelines [39], the MGFT department is currently using for the genetic investigation of the CYP21A2 gene the gold standard method of Sanger sequencing and the multiplex ligation-dependent probe amplification (MLPA) [2, 3, 26, 37, 38]. This evidence concerns the gene CYP21A2 and congenital adrenal hyperplasia.